Literature DB >> 11498762

Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-gamma gene into lung cancer.

M Noguchi1, K Imaizumi, T Kawabe, H Wakayama, Y Horio, Y Sekido, T Hara, N Hashimoto, M Takahashi, K Shimokata, Y Hasegawa.   

Abstract

CD40-CD40 ligand (CD40L) interaction is an important costimulatory signaling pathway in the crosstalk between T cells and antigen-presenting cells. This receptor-ligand system is known to be essential in eliciting strong cellular immunity. Here we demonstrate that murine lung cancer cells (3LLSA) transduced with the CD40L gene (3LLSA-CD40L) were rejected in syngeneic C57BL/6 mice, but grew in CD40-deficient mice to the same extent as control tumor cells. Immunohistochemical study showed that inflammatory cells, including CD4+, CD8+ T cells and NK cells, infiltrated into the inoculated 3LLSA-CD40L tumor tissue. Inoculation of 3LLSA-CD40L cells into mice resulted in the induction of 3LLSA-specific cytotoxic T-cell immunity, and the growth of parental 3LLSA tumors was inhibited when 3LLSA cells were inoculated into C57BL/6 mice mixed with 3LLSA-CD40L cells or when they were rechallenged 4 weeks after 3LLSA-CD40L cells were rejected. Furthermore, co-inoculation of interferon (IFN)-gamma-transduced cells (3LLSA-IFNgamma) with 3LLSA-CD40L cells enhanced the antitumor immunity efficiently in vivo. These results indicate that the in vivo priming with CD40L- and IFN-gamma gene-transduced lung cancer cells is a promising strategy for inducing antitumor immunity in the treatment of lung cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11498762     DOI: 10.1038/sj.cgt.7700320

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  7 in total

1.  Construction of recombinant eukaryotic expression plasmid containing murine CD40 ligand gene and its expression in H22 cells.

Authors:  Yong-Fang Jiang; Yan He; Guo-Zhong Gong; Jun Chen; Chun-Yan Yang; Yun Xu
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

2.  Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis.

Authors:  Naozumi Hashimoto; Sem H Phan; Kazuyoshi Imaizumi; Masaki Matsuo; Harunori Nakashima; Tsutomu Kawabe; Kaoru Shimokata; Yoshinori Hasegawa
Journal:  Am J Respir Cell Mol Biol       Date:  2009-09-18       Impact factor: 6.914

3.  CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy.

Authors:  Sadia Zafar; Suvi Sorsa; Mikko Siurala; Otto Hemminki; Riikka Havunen; Victor Cervera-Carrascon; João Manuel Santos; Hongjie Wang; Andre Lieber; Tanja De Gruijl; Anna Kanerva; Akseli Hemminki
Journal:  Oncoimmunology       Date:  2018-08-15       Impact factor: 8.110

4.  Cationic liposome-mediated transfection of CD40 ligand gene inhibits hepatic tumor growth of hepatocellular carcinoma in mice.

Authors:  Yong-fang Jiang; Jing Ma; Yan He; Yong-hong Zhang; Yun Xu; Guo-zhong Gong
Journal:  J Zhejiang Univ Sci B       Date:  2009-01       Impact factor: 3.066

5.  Timing is critical for an effective anti-metastatic immunotherapy: the decisive role of IFNγ/STAT1-mediated activation of autophagy.

Authors:  Jun Yan; Zi-Yan Wang; Hong-Zhen Yang; Han-Zhi Liu; Su Mi; Xiao-Xi Lv; Xiao-Ming Fu; Hui-Min Yan; Xiao-Wei Zhang; Qi-Min Zhan; Zhuo-Wei Hu
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240

Review 6.  CD40/CD40 ligand interactions in immune responses and pulmonary immunity.

Authors:  Tsutomu Kawabe; Miyoko Matsushima; Naozumi Hashimoto; Kazuyoshi Imaizumi; Yoshinori Hasegawa
Journal:  Nagoya J Med Sci       Date:  2011-08       Impact factor: 1.131

7.  Protective effect of geranylgeranylacetone, an inducer of heat shock protein 70, against drug-induced lung injury/fibrosis in an animal model.

Authors:  Takayoshi Fujibayashi; Naozumi Hashimoto; Mayumi Jijiwa; Yoshinori Hasegawa; Toshihisa Kojima; Naoki Ishiguro
Journal:  BMC Pulm Med       Date:  2009-09-16       Impact factor: 3.317

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.